Generic tacrolimus

Phase 1Small molecule

Novartis

Generic tacrolimus is one of 58 small molecule programs targeting Kidney Transplant. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

CataractActive, not recruiting

Kidney TransplantPhase 1

Active, not recruiting

CataractPhase 1

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Simulect

Novartis

Preclinical

15 3

Medrol

Pfizer

Preclinical

12 4

Zinbryta

Roche

Preclinical

6 5

Zemplar

AbbVie

Preclinical

2 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Sensipar

Amgen

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 9

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Transplant2 trials

A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac

Completed·VVastra Gotaland Region··NCT02587052·186 enrolled

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

Completed· Novartis logo

Novartis·Phase 4·NCT01256294·71 enrolled

Kidney Transplant1 trial

Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.

Withdrawn· Novartis logo

Novartis·Phase 1·NCT03978494

Cataract1 trial

Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery

Completed· Novartis logo

Novartis·Phase 1·NCT03531697·381 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Generic tacrolimus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Generic tacrolimus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Generic tacrolimus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novartis

Generic tacrolimus

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Transplant2 trials

Kidney Transplant1 trial

Cataract1 trial

References

Drug Info

Quick Facts

Related News